Jonathan Dow
Graduate Student, Therapeutic RadiologyAbout
Research
Publications
2025
PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7
Colón-Ríos D, Dow J, Krysztofiak A, Liu Y, Rogers F, Glazer P. PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. NAR Cancer 2025, 7: zcaf047. PMID: 41357766, PMCID: PMC12675010, DOI: 10.1093/narcan/zcaf047.Peer-Reviewed Original ResearchThis study investigates how IDH1-mutant cancers develop resistance to PARP inhibitors through loss of end protection factors, 53BP1 and REV7, and shows that the drug cediranib can overcome this resistance, highlighting potential therapeutic strategies for improving cancer treatment outcomes.
2022
Chapter 11 Oncometabolites, epigenetic marks, and DNA repair
Dow J, Glazer P. Chapter 11 Oncometabolites, epigenetic marks, and DNA repair. 2022, 191-202. DOI: 10.1016/b978-0-323-91081-1.00008-x.Peer-Reviewed Original ResearchDNA damage repairJmjC domain-containing histone demethylasesDamage repairDouble-strand break sitesHallmarks of cancerEpigenetic marksHistone demethylasesEpigenetic signalingDNA demethylaseDependent dioxygenasesEpigenetic mechanismsDNA repairMajor translational impactGenomic instabilityMethylation signalsRepair pathwaysBreak siteDNA hypermethylationDNA damageΑ-ketoglutarateGlobal histoneOncometaboliteCancer cellsCompetitive inhibitorProfound sensitivity
2021
Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair
Dow J, Krysztofiak A, Liu Y, Colon-Rios DA, Rogers FA, Glazer PM. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. Molecular Cancer Research 2021, 19: 2057-2067. PMID: 34535560, PMCID: PMC8642278, DOI: 10.1158/1541-7786.mcr-21-0456.Peer-Reviewed Original ResearchConceptsHistone deacetylase inhibitor vorinostatPatient-derived tumor xenograftsHomology-directed repairIsocitrate dehydrogenase 1/2 mutationsHistone deacetylase inhibitionIDH1 mutant cellsGreater cell deathHDACi treatmentInhibitor vorinostatTumor xenograftsDeacetylase inhibitionIDH1/2 mutationsPotential biomarkersSpecific cancersMutant cancersCancerCancer cellsDNA repair defectsMalignancyVorinostatDNA double-strand breaksGliomasHistone hypermethylationCell deathPARPi
2020
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
Sulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, Noronha K, Bao X, Li J, Shuch BM, King MC, Bindra RS, Glazer PM. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature 2020, 582: 586-591. PMID: 32494005, PMCID: PMC7319896, DOI: 10.1038/s41586-020-2363-0.Peer-Reviewed Original ResearchConceptsDNA repairDNA breaksFumarate hydrataseDownstream repair factorsHistone 3 lysine 9Homology-dependent repairPoly (ADP-ribose) polymeraseRecruitment of TIP60Deregulation of metabolismChromatin signalingSuccinate dehydrogenase genesGenome integrityLysine 9Repair factorsDehydrogenase geneEnd resectionIsocitrate dehydrogenase 1Aberrant hypermethylationMechanistic basisSomatic mutationsDehydrogenase 1GenesHuman malignanciesProper executionMutations